Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 23 | -0.32 Decreased by -14.29% | -0.29 Decreased by -10.34% |
| Aug 10, 23 | -0.01 Increased by +96.77% | -0.2 Increased by +95% |
| May 15, 23 | -0.29 Increased by +9.38% | -0.09 Decreased by -222.22% |
| Mar 16, 23 | -0.3 Increased by +11.76% | -0.3 |
| Nov 14, 22 | -0.28 Increased by +15.15% | -0.3 Increased by +6.67% |
| Aug 11, 22 | -0.31 Increased by +8.82% | -0.3 Decreased by -3.33% |
| May 12, 22 | -0.32 Decreased by -28% | -0.31 Decreased by -3.23% |
| Mar 17, 22 | -0.34 Decreased by -47.83% | -0.26 Decreased by -30.77% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -33.88 M Decreased by -22.55% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 31.02 M Increased by +N/A% | -808 K Increased by +97.34% | Decreased by -2.61% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -35.08 M Decreased by -13.04% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -36.38 M Decreased by -37.06% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -27.65 M Decreased by -21.89% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -30.42 M Decreased by -30.99% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -31.04 M Decreased by -76.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -26.54 M Decreased by -68.52% | Decreased by N/A% Decreased by N/A% |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc.